Navigation Links
TGV-Inhalonix Receives Orphan Drug Status for its Novel Antibiotic to Treat Resistant Infections in Cystic Fibrosis
Date:4/12/2016

NEW YORK, April 12, 2016 /PRNewswire/ -- TGV-Inhalonix, Inc., a New York-based pharmaceutical company, today announced that its new drug candidate for treating antibiotic-resistant bacterial lung infections in patients with cystic fibrosis has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA).

Logo - http://photos.prnewswire.com/prnh/20160412/354403LOGO

The FDA granted the special status for TGV-Inhalonix's antimicrobial agent Mul-1867.

"This is a breakthrough for our novel drug candidate, which has shown good results in early studies," said Dr. Victor Tetz, chief scientific advisor at TGV-Inhalonix.

"Previous studies have shown that Mul-1687 holds promise as a treatment for life-threatening pulmonary infections from Pseudomonas aeruginosa, Burkholderia cepacia, and other bacteria," said Dr. George Tetz, drug development advisor, at TGV-Inhalonix. "Our research revealed that Mul-1867 is more effective against antibiotic-resistant pathogens as compared with other drugs commonly used for the treatment of infections in cystic fibrosis patients."

The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics. The FDA defines rare diseases as those affecting fewer than 200,000 people in the United States at any given time.

The FDA granted the Orphan Drug Designation for Mul-1687 after reviewing multiple experimental research findings by TGV-Inhalonix. TGV-Inhalonix said its research indicates Mul-1867 holds promise for addressing unmet need for improved treatment of antibiotic-resistant pulmonary infections.

According to the Cystic Fibrosis Foundation, the median predicted survival age in persons with cystic fibrosis in the United States is 39.3 years. Chronic pulmonary infections lead to progressive decline in lung function and eventually respiratory failure in patients with cystic fibrosis.

TGV-Inhalonix also believes Mul-1867's unique mechanism offers a broad potential for the treatment of various bacterial and fungal infections, including respiratory tract infections in COPD patients, ventilator-associated pneumonia (VAP), and fungal pneumonia.

"Taken together, our data suggest that Mul-1867 is a promising novel antimicrobial agent that has potent broad-spectrum antibacterial activity against clinically important microorganisms," said Dr. Sushant Kumar, a member of TGV's advisory board. "TGV-Inhalonix has completed comprehensive preclinical and pilot clinical studies of Mul-1867 in Europe, showing good efficacy and safety profile in cystic fibrosis patients. Regarding development in the US, the company plans to conduct Investigational New Drug studies (IND) studies with an IND filing expected in 2018."

Mul-1867 data have been published in several scientific journals and were presented at major microbiology and infectious disease conferences including ASM-2015 and ICAAC-2015.

TGV-Inhalonix is a New York-based Research & Development pharmaceutical company that provides a broad range of innovative products that are developed, manufactured and marketed worldwide by TGV-Laboratories Group of Companies. The research of the TGV-Laboratories Group of Companies is focused on identifying new causes for diseases, as well as blueprinting and creating small molecules and recombinant proteins.

For more information about Victor and George Tetz and TGV-Inhalonix, please contact Max Smetannikov, MVG at 917 310 3396, Email, or Jeri Clausing at 505-221-3108, Email.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tgv-inhalonix-receives-orphan-drug-status-for-its-novel-antibiotic-to-treat-resistant-infections-in-cystic-fibrosis-300250196.html


'/>"/>
SOURCE TGV-Inhalonix
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Oramed Receives Patent Term Adjustment Extending the Term of Its U.S. Patent
2. Raymond Sanchez Receives ISCDD Leadership Award at ISCDD 2016 Annual Meeting
3. Edwards Lifesciences Receives Approval For SAPIEN 3 Valve In Japan
4. Arcturus Therapeutics Receives Intent to Grant Notice from the European Patent Office for their Unlocked Nucleomonomer Agent (UNA) Technology
5. CardiacAssist Receives FDA 510(k) Clearance For Its TandemLung Oxygenator
6. Mass. Start-up Interscope Receives European Regulatory Approval, Secures Five U.S. Patents for Medical Devices Innovation
7. Alexza Pharmaceuticals Receives Positive Nasdaq Listing Determination
8. Katama Pharmaceuticals Receives a Notice of Allowance of a Composition of Matter Patent For Tolperisone
9. BD Receives FDA Approval for New Automated Cervical Cancer Screening System
10. Corvia Medical Receives IDE Approval For REDUCE LAP-HF I Clinical Study & Announces Agreement With Strategic Partner For Exclusive Option To Purchase Company
11. Edwards SAPIEN XT Valve Receives FDA Approval For Pulmonic Procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... (PRWEB) , ... July 17, 2019 , ... The American ... APNA Board of Directors and 2020 Nominating Committee . Elected by psychiatric-mental health nurse ... APNA 33rd Annual Conference in New Orleans, LA, October 2-5, 2019. , ...
(Date:7/17/2019)... ... July 17, 2019 , ... ... solution needed to attract new customers, better engage existing patients and collaborate with ... digital marketing services in tandem with an all-in-one platform. With the Updox approach, ...
(Date:7/17/2019)... LOS ANGELES (PRWEB) , ... July 17, 2019 , ... ... Angeles to reclaim their smiles with Kanani's innovated bonding procedures. Bonding is just one ... other methods, bonding can be done in a single visit, and patients leave immediately ...
Breaking Medicine Technology:
(Date:7/17/2019)... SAN DIEGO (PRWEB) , ... July 17, 2019 , ... ... not become parents. Every Intended Parents’ story differs , but, in addition to ... their Surrogate. , Across the globe, more and more Intended Parents are electing to ...
(Date:7/17/2019)... ... July 17, 2019 , ... Dr. Jonathan Zaidan, MD, FACOG, President ... WJR’s Health Woman Show. The show airs on Wednesday, July 17ths at 7pm. ... , Dr. Zaidan and co-host Ann Thomas discuss the challenges that women face when ...
(Date:7/13/2019)... , ... July 12, 2019 , ... ... YCBD), has been named a “Brand to Watch” by Brightfield Group, a leading ... cbdMD in the top 10 of domestic CBD companies in two categories, Topicals ...
(Date:7/11/2019)... ... 2019 , ... Swagelok Southeast Texas, a distributor for Ohio-based ... acquisition of another Houston-area distributor. The acquisition of the Swagelok Central Houston facility ... Nederland and Houston. , With this expansion, Swagelok Southeast Texas also extends ...
(Date:7/10/2019)... ... 10, 2019 , ... HMP, a leader in healthcare events and education, today ... Pathways Congress, taking place October 11-13, 2019 in Boston. , Launched in 2016, the ... the expansion of clinical pathways as a decision support tool and their increasing influence ...
Breaking Medicine News(10 mins):